At the ESC Congress 2025 that took place in Madrid, Novo Nordisk presented findings from the STEER study, which indicated that Wegovy (semaglutide 2.4 mg) provides greater protection to cardiovascular risk than tirzepatide for people living with...
Merck announced today positive topline data from its phase 3 CORALreef Lipids trial of enlicitide, an investigational oral PCSK9 inhibitor, in adults with hypercholesterolemia. The once-daily regimen achieved all primary and key secondary...
Novartis reported encouraging findings from V-DIFFERENCE, a phase IV study comparing Leqvio (inclisiran) to a placebo, both of which were given in addition to individually tailored lipid-lowering therapy (LLT), in patients with hypercholesterolemia
AstraZeneca plans to apply for regulatory approval for Blood Pressure Drug Baxdrostat before the end of this year, with approval expected in the U.S. and E.U. in 2026. The company views the opportunity in Baxdrostat as the crux of its strategy...
Mahajan Imaging & Labs, a pioneer in integrated diagnostics and advanced medical imaging, has entered a strategic alliance with Fortis La Femme, India’s leading hospital dedicated to women’s and children’s health, to create a new benchmark in...
Eli Lilly and Company announced positive top-line results in the Phase 3 ATTAIN-2 trial that evaluated, orforglipron, an investigational oral GLP-1 receptor agonist in adults with obesity or overweight and type 2 diabetes. The ATTAIN-2 trial showed
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. market availability of the first generic version of Saxenda
MedGenome unveiled the first CNS Tumour Methylation Classifier Test in India, which is a futuristic diagnostic tool that can recognize and categorize
Health Canada has licensed Ozempic (semaglutide injection) as the first-and-only drug to be used for once-weekly treatment of type 2 diabetes (T2D) and for the reduction of the risk of progression of kidney disease, end-stage kidney di...
A new treatment by Pfizer’s Padcev and Merck’s Keytruda is showing positive results in patients with advanced bladder cancer. A recent study looked at these two drugs combined and showed that they helped patients live longer and delayed...
.jpg)
.jpg)
, CDSCO.jpg)